Tuberculosis Biomarkers: From Diagnosis to Protection.
Tuberculosis Biomarkers: From Diagnosis to Protection.
复制标题
DOI：
10.4081/idr.2016.6568
复制
发表时间：
2016-06-24
影响因子：
3.2
通讯作者：
Ottenhoff TH
中科院分区：
文献类型：
--
作者：
Goletti D;Petruccioli E;Joosten SA;Ottenhoff TH
需要在全球范围内采取新的方法来控制结核病。特别是，需要新的诊断工具和新的生物标志物来评估病原体和宿主对感染的反应的关键要素。非痰基诊断测试、预测对治疗的充分反应性的生物标志物和发展活动性TB疾病的风险的生物标志物是主要目标。在这里，我们回顾了该领域的现状。虽然关于新的候选生物标志物的报道很多，但验证和独立确认很少。需要努力减少候选生物标志物的探索性上游鉴定与针对不同人群中的明确临床终点验证生物标志物之间的差距。这将需要科学家和资助机构的重大承诺。
New approaches to control tuberculosis (TB) worldwide are needed. In particular, new tools for diagnosis and new biomarkers are required to evaluate both pathogen and host key elements of the response to infection. Non-sputum based diagnostic tests, biomarkers predictive of adequate responsiveness to treatment, and biomarkers of risk of developing active TB disease are major goals. Here, we review the current state of the field. Although reports on new candidate biomarkers are numerous, validation and independent confirmation are rare. Efforts are needed to reduce the gap between the exploratory up-stream identification of candidate biomarkers, and the validation of biomarkers against clear clinical endpoints in different populations. This will need a major commitment from both scientists and funding bodies.